Why SELLAS Life Sciences Group (SLS) Stock Is Up Today

SELLAS Life Sciences Group (SLS) is up 10.5% today. Here is some analysis on what might have caused this price movement. ([stockanalysis.com](https://stockanalysis.com/stocks/sls/forecast/))

Analysis: The most likely driver is continued investor anticipation around SELLAS's pivotal Phase 3 REGAL trial in acute myeloid leukemia, with the company previously stating that 78 of the 80 required events had occurred as of May 11, 2026. The rally may also be getting support from strong liquidity and bullish analyst target increases earlier in July, while some of today's move could simply reflect speculative biotech momentum ahead of a major readout. ([s203.q4cdn.com](https://s203.q4cdn.com/139585304/files/doc_news/SELLAS-Life-Sciences-Reports-First-Quarter-2026-Financial-Results-and-Provides-Corporate-Update-2026.pdf?utm_source=openai))

Details:

In its first-quarter 2026 corporate update, SELLAS said the REGAL study had reached 78 events out of the 80 needed for final analysis, leaving the stock highly sensitive to any expectations around a near-term trial milestone. ([s203.q4cdn.com](https://s203.q4cdn.com/139585304/files/doc_news/SELLAS-Life-Sciences-Reports-First-Quarter-2026-Financial-Results-and-Provides-Corporate-Update-2026.pdf?utm_source=openai))

SELLAS disclosed on June 2 that it had $107.1 million in cash at March 31, 2026, and then received about $28.7 million from warrant exercises in April and May, which likely reduced immediate financing pressure. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1390478/000110465926069251/tm2616601d1_8k.htm))

Analyst sentiment turned more bullish this month, with two tracked firms lifting price targets to $25 and $30 in early July while maintaining buy ratings. ([stockanalysis.com](https://stockanalysis.com/stocks/sls/forecast/))

A late-June SEC filing amended executive employment and severance terms; this could be routine governance work, but some investors may be interpreting it as part of broader strategic positioning. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1390478/000110465926077556/tm2618927d1_8k.htm?utm_source=openai))

Sources:

SEC, SELLAS Life Sciences, Stock Analysis

Disclaimer: This price movement analysis was generated with the help of AI. Please double-check the information provided for mistakes.

EARLY ACCESS

Receive SLS Data Alerts

Real-time alerts on filings, insider trades, and market signals — before everyone else.

Get Alerts →

$SLS Hedge Fund Activity

We have seen 109 institutional investors add shares of $SLS stock to their portfolio, and 28 decrease their positions in their most recent quarter.

Here are some of the largest recent moves:

STATE STREET CORP added 6,208,185 shares (+283.7%) to their portfolio in Q1 2026, for an estimated $26,260,622
BLACKROCK, INC. added 4,657,356 shares (+61.8%) to their portfolio in Q1 2026, for an estimated $19,700,615
JONES FINANCIAL COMPANIES LLLP added 1,245,834 shares (+290.2%) to their portfolio in Q1 2026, for an estimated $5,269,877
MILLENNIUM MANAGEMENT LLC removed 1,228,325 shares (-88.5%) from their portfolio in Q1 2026, for an estimated $5,195,814
GEODE CAPITAL MANAGEMENT, LLC added 835,269 shares (+27.1%) to their portfolio in Q1 2026, for an estimated $3,533,187
UBS GROUP AG added 696,692 shares (+1429.8%) to their portfolio in Q1 2026, for an estimated $2,947,007
MARSHALL WACE, LLP added 696,494 shares (+52.0%) to their portfolio in Q1 2026, for an estimated $2,946,169

To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.

This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.